Celgene Corp. (CELG)

79.51
0.07 0.09
NASDAQ : Health Technology
Prev Close 79.44
Open 79.88
Day Low/High 78.57 / 80.15
52 Wk Low/High 74.13 / 147.17
Volume 3.50M
Avg Volume 6.76M
Exchange NASDAQ
Shares Outstanding 724.83M
Market Cap 56.34B
EPS 3.80
P/E Ratio 21.65
Div & Yield N.A. (N.A)

Latest News

Jim Cramer: A GLUM Index For Gloomy Markets

Jim Cramer: A GLUM Index For Gloomy Markets

Taking the measure of what's keeping the markets in the dumps.

Okta, Celgene, Altria: 'Mad Money' Lightning Round

Okta, Celgene, Altria: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Okta, Celgene, GasLog Partners, Neutral Tandem, Altria, Axovant Sciences, Lowe's and more.

Tread Carefully: Cramer's 'Mad Money' Recap (Friday 6/15/18)

Tread Carefully: Cramer's 'Mad Money' Recap (Friday 6/15/18)

Jim Cramer says investors need to be cautious, as trade tensions are just one of the things causing markets to whiplash. But he's got your game plan for next week.

Results Of Phase III RELEVANCE Study Comparing REVLIMID Plus Rituximab (R2) Versus Rituximab Plus Chemotherapy In Patients With Previously Untreated Follicular Lymphoma To Be Presented At ASCO 2018

Results Of Phase III RELEVANCE Study Comparing REVLIMID Plus Rituximab (R2) Versus Rituximab Plus Chemotherapy In Patients With Previously Untreated Follicular Lymphoma To Be Presented At ASCO 2018

Celgene Corporation (NASDAQ:CELG) today announced additional results from RELEVANCE, a phase III, randomized, open-label, international clinical study conducted in partnership with the Lymphoma Academic Research Organisation (LYSARC), were presented at...

General Electric, Celgene, Dollar Tree: 'Mad Money' Lightning Round

General Electric, Celgene, Dollar Tree: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at General Electric, Celgene, Dollar Tree, STMicroelectronics, Chico's, Campbell Soup, Copart, Yext and more.

Good Job Growth, Low Inflation: Cramer's 'Mad Money' Recap (Friday 6/1/18)

Good Job Growth, Low Inflation: Cramer's 'Mad Money' Recap (Friday 6/1/18)

Jim Cramer says the market like this economy; he has your game plan for next week.

Results Of Phase III OPTIMISMM Study Presented At ASCO 2018 Showed The PVd Triplet Improved PFS In Early Lines Of Relapsed Or Refractory Multiple Myeloma

Results Of Phase III OPTIMISMM Study Presented At ASCO 2018 Showed The PVd Triplet Improved PFS In Early Lines Of Relapsed Or Refractory Multiple Myeloma

Celgene Corporation (NASDAQ:CELG) today announced results from the OPTIMISMM study, a phase III, randomized, open-label, international clinical study of the investigational combination regimen of POMALYST ® (pomalidomide), bortezomib and dexamethasone in...

FDA Moves to Make Life Easier for Generic Drug Companies

FDA Moves to Make Life Easier for Generic Drug Companies

Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.

Celgene Corporation Announces Hiring Of David V. Elkins As Executive Vice President, Chief Financial Officer And Appointment Of Peter N. Kellogg To Executive Vice President, Chief Corporate Strategy Officer

Celgene Corporation Announces Hiring Of David V. Elkins As Executive Vice President, Chief Financial Officer And Appointment Of Peter N. Kellogg To Executive Vice President, Chief Corporate Strategy Officer

Celgene Corporation (NASDAQ:CELG) today announced the hiring of David V. Elkins as Executive Vice President (EVP), Chief Financial Officer (CFO).

The Long Decline in Celgene Stock Could Finally Be Over

The Long Decline in Celgene Stock Could Finally Be Over

Here's our new strategy for the shares.

CELGENE 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against Celgene Corporation - CELG

CELGENE 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against Celgene Corporation - CELG

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Celgene Corporation (NasdaqGS: CELG).

Emboldened By Biotech Names

Emboldened By Biotech Names

For the trade, I'm opting to use the iShares Nasdaq Biotechnology ETF.

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Stocks fall Thursday after Donald Trump calls off a summit meeting planned for next month with North Korea leader Kim Jong Un.

Celgene Shares Rise on Plans to Increase Stock Buybacks

Celgene Shares Rise on Plans to Increase Stock Buybacks

The Summit, N.J.-based biotech firm also plans to enter into an accelerated share repurchase program to buy back $2 billion of stock.

Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization And Plans To Execute A $2 Billion Accelerated Share Repurchase Program

Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization And Plans To Execute A $2 Billion Accelerated Share Repurchase Program

Celgene Corporation (NASDAQ: CELG) today announced that the Company's Board of Directors authorized the repurchase of an additional $3 billion of the Company's common stock.

Celgene Corp Becomes Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Celgene To Present New Clinical Data In Blood Cancer And Solid Tumor Therapies At Upcoming American Society Of Clinical Oncology (ASCO) Scientific Sessions

Celgene To Present New Clinical Data In Blood Cancer And Solid Tumor Therapies At Upcoming American Society Of Clinical Oncology (ASCO) Scientific Sessions

Celgene Corporation (NASDAQ: CELG) today announced that data from more than 60 company-sponsored, cooperative group and investigator-initiated clinical studies evaluating Celgene agents will be presented at the American Society of Clinical Oncology Annual...

Celgene Corporation To Webcast At Upcoming Investor Conferences And Events

Celgene Corporation To Webcast At Upcoming Investor Conferences And Events

Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences and events where Celgene management will provide an overview of the Company.

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.

What to Expect From Trump's Speech on Drug Prices on Friday

What to Expect From Trump's Speech on Drug Prices on Friday

Since taking office, President Trump has talked big on reining in drug prices, but the administration's lack of action leaves most expecting a May 11 speech that tastes like a nothing burger.

CLASS UPDATE: The Klein Law Firm Reminds Investors Of A Class Action Commenced On Behalf Of Celgene Corporation Shareholders And A Lead Plaintiff Deadline Of May 29, 2018 (CELG)

CLASS UPDATE: The Klein Law Firm Reminds Investors Of A Class Action Commenced On Behalf Of Celgene Corporation Shareholders And A Lead Plaintiff Deadline Of May 29, 2018 (CELG)

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Celgene Corporation (NASDAQ: CELG) who purchased shares between January 12, 2015 and February 27, 2018.

CELG EXPANDED CLASS: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Celgene Corporation And A Lead Plaintiff Deadline Of May 29, 2018

CELG EXPANDED CLASS: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Celgene Corporation And A Lead Plaintiff Deadline Of May 29, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Celgene Corporation ("Celgene") (NASDAQ:CELG) securities...

CELGENE SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Celgene Corporation - CELG

CELGENE SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Celgene Corporation - CELG

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Celgene Corporation (NasdaqGS: CELG), if they purchased the Company's...

TheStreet Quant Rating: C (Hold)